Scandinavian Biopharma is strengthening its organization by recruiting Anna Hill to the new position as Clinical Operations Manager.
Anna Hill will have the overall responsibility for the company’s clinical development program and be responsible for ensuring that ongoing and future clinical trials are performed in a compliant and efficient manner. She has solid experience from similar positions at pharmaceutical companies such as Moberg Pharma and Amgen.
“I am very excited to contribute in developing the clinical trial business of an innovative and expanding company like Scandinavian Biopharma. I really look forward to be a part in the development of a vaccine that significantly can have an impact on the global health. In this position I can combine my past experiences with the strong driving force that exists at Scandinavian Biopharma,” says Anna Hill.
ETVAX clinical trial programs in Africa
Initially, Hill focus will be on ETVAX clinical trial programs in Africa. In 2019, a phase I study was started in Zambia aiming to establish the optimal dose of ETVAX for children and to investigate the benefits of a booster dose. The Zambia study will be followed by a Phase IIb study in Gambia with the aim of establishing the safety, immune response and protective effect of ETVAX.
“To be able to implement our ambitious clinical development program we needs to strengthen the organisation within Clinical Operations. Anna’s experience and skills will be very important for us and I am very pleased to welcome her to Scandinavian Biopharma,” says Björn Sjöstrand, CEO of Scandinavian Biopharma.
